Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1386-1394

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 930-939

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 11, 2015-11 ,pp. : 2828-2836

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1537-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti‐interleukin‐6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis

By  

EUROPEAN JOURNAL OF IMMUNOLOGY, Vol. 48, Iss. 1, 2018-01 ,pp. : 194-203

John Wiley & Sons Inc

Access to resources Recommend Favorite